The present invention relates to methods for generating Induced Pluripotent Stem Cells from fibroblast cells. The invention also relates to appropriate culture media used by the method disclosed; pluripotent stem cells, cultures of the pluripotent stem cells, differentiated cells derived from the culture pluripotent stem cells isolated by the methods disclosed and uses for those cells, e.g. therapeutic uses, such as autologous cell therapy procedures.

A decidual placental mesenchymal stem cell and its culturing method are provided, which includes adding an induction step to the conventional mesenchymal stem cell culture method to make the said decidual placental mesenchymal stem cell highly express the decoy receptor 3; DcR3. A use of decidual placental mesenchymal stem cells for preparing pharmaceutical compositions for promoting angiogenesis.

The present invention discloses formulation of a serum-free medium used for human pluripotent stem cells, which comprises the following raw materials: inorganic salt components, organic components, amino acids and amino acid salts, energy substances and metabolic intermediates, vitamins and antioxidants, proteins and polypeptides, trace elements and chromogenic substances; while the culture process comprises the following steps: selecting a basic formulation, performing combination screening, identifying and evaluating results, and testing a new formulation of culture; and proportioning according to the following methods: adding aforesaid raw materials into 950 ml of water for injection, stirring gently until dissolved, and finally adding 2.438 g of sodium bicarbonate, and stirring gently until dissolved, and then adding 1 liter of water for injection, adjusting the pH to the desired value with 1 mol/L sodium hydroxide solution or 1 mol/L hydrochloric acid solution, finally filtering sterilized with 0.1 μm diameter filter under positive pressure, and storing the medium solution in dark place at 2° C.-8° C., the invention solves the problem of high cost of domestic import of serum-free formulation.

Glycoproteins that are transgenically produced in mammalian cells exhibit non-human glycan structures. As in humans, this can possibly lead to immune responses, the drug manufacturing potential of these drugs is limited. On the other hand, recombinant protein production in human cells is inefficient due to the cells' poor protein yields, proliferation potential and cellular density. The present application solves these issues by providing a recombinant vertebrate cell that is comprising a non-vertebrate and/or artificial phosphatidylethanolamine-binding protein (PEBP). Compared to a parent cell line, the recombinant cells of the invention exhibit improved cell growth, protein yield and excellent compatibility with other established protein production methods. Furthermore, methods, for producing a cell line with improved vitality, protein expression and cell growth characteristics by introducing a non-vertebrate and/or artificial PEBP is given. Moreover, both a nucleic acid construct that is suitable for regulating recombinant protein expression in a cell by coding for such a PEBP and a recombinant cell comprising such a nucleic acid construct is provided. Lastly, a method for the recombinant expression of a target protein by culturing such a recombinant vertebrate cell of the invention is given, wherein the cell is also comprising an expression construct encoding the target protein.

The present invention relates to methods for obtaining a substantially pure population of pluripotent stem cell-derived airway basal-like cells. It also relates to a method of obtaining an in vitro pluripotent stem cell-derived airway epithelium model, utilising the pluripotent stem cell-derived airway basal-like cells. The invention further relates to an in vitro airway epithelial model, or lung model, which can be used for disease modelling and/or drug screening and in particular to an in vitro model for SARS-CoV-2 infection and for screening for agents effective against infection with SARS-CoV-2 i.e. COVID-19 and methods of using the same.

The present disclosure provides methods of evaluating a therapeutic agent for cancer, and methods of cancer treatment.

The invention relates to a serum-free cell culture perfusion medium comprising the medium components subgrouped into at least three separate aqueous concentrated feeds and a diluent, wherein the resulting serum-free cell culture perfusion medium is pH-adjusting to neutral pH upon mixing. Also provided is a method of preparing said serum-free cell culture perfusion medium. The invention further relates to methods of culturing mammalian cells or producing a protein of interest in perfusion culture using said serum-free cell culture perfusion medium that achieve high productivity at a low cell specific perfusion rate. The invention further relates to the use of the new and improved serum-free cell culture perfusion medium to control osmolality in a perfusion cell culture, wherein increasing osmolality results in an increase in total productivity and/or cell specific productivity by suppressing cell growth during cell culture, e.g., during production phase of perfusion cell culture. Suppression of cell growth particularly reduces or eliminates the need for wasteful cell bleed.

The present invention provides in vitro methods of differentiating brain mural cells and methods of use, including use in blood brain barrier models. Suitable in vitro derived cell populations of brain mural cells are also provided.

The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier.

A method for culturing a bovine progenitor cell, comprising the step of: culturing a bovine progenitor cell in a serum-free medium for culturing a bovine progenitor cell, wherein said serum-free medium comprises an albumin; and a fibroblast growth factor (FGF).